Shao-Lee Lin insider trades: Cue Biopharma (CUE) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Shao-Lee reports to the SEC
Open-market buys and sales
5 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Oct 12, 2026 | CUE | ↓ Sell | 11,087 | $27.55 | $305K | Direct | Oct 14, 2026 (2d) |
| Aug 13, 2026 | CUE | ↓ Sell | 58,258 | $27.58 | $1.6M | Direct | Aug 14, 2026 (1d) |
| Apr 1, 2024 | SLRN | ↓ Sell | 9,961 | $6.63 | $66K | Direct | Apr 3, 2024 (2d) |
| Feb 20, 2024 | SLRN | ↓ Sell | 15,701 | $7.60 | $119K | Direct | Feb 22, 2024 (2d) |
| Jan 2, 2024 | SLRN | ↓ Sell | 10,691 | $7.41 | $79K | Direct | Jan 4, 2024 (2d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other CUE insiders
Open-market trades in the last 12 months
About Shao-Lee Lin's insider trades
Shao-Lee Lin is Chief Executive Officer at Cue Biopharma (CUE). Since Jan 2, 2024, Shao-Lee has reported no open-market purchases and 5 sales worth $2.2M on SEC Form 4. In the last 12 months: 2 sales ($1.9M).
Their filings also include grants and awards (20 filings), shares withheld for taxes (5 filings), option exercises (3 filings), other transactions (3 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every CUE insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.